PHENTERMINE- phentermine hydrochloride capsule

Phentermine by

Drug Labeling and Warnings

Phentermine by is a Prescription medication manufactured, distributed, or labeled by Aurolife Pharma, LLC, Aurolife Pharma LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS & USAGE

    Phentermine hydrochloride Capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m2, or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

    Below is a chart of body mass index (BMI) based on various heights and weights.

    BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.


    BODY MASS INDEX (BMI), kg/m2
    Height (fe
    et, inches)

    Weight
    (pounds)
    		5’0”
    		5’3”
    		5’6”
    		5’9”
    		6’0”
    		6’3”
    140
    		27
    		25
    		23
    		21
    		19
    		18
    150
    		29
    		27
    		24
    		22
    		20
    		19
    160
    		31
    		28
    		26
    		24
    		22
    		20
    170
    		33
    		30
    		28
    		25
    		23
    		21
    180
    		35
    		32
    		29
    		27
    		25
    		23
    190
    		37
    		34
    		31
    		28
    		26
    		24
    200
    		39
    		36
    		32
    		30
    		27
    		25
    210
    		41
    		37
    		34
    		31
    		29
    		26
    220
    		43
    		39
    		36
    		33
    		30
    		28
    230
    		45
    		41
    		37
    		34
    		31
    		29
    240
    		47
    		43
    		39
    		36
    		33
    		30
    250
    		49
    		44
    		40
    		37
    		34
    		31

    The limited usefulness of agents of this class, including phentermine, [see Clinical Pharmacology (12.1, 12.2)] should be measured against possible risk factors inherent in their use such as those described below.

  • 2 DOSAGE & ADMINISTRATION

    2.1 Exogenous Obesity


    Dosage should be individualized to obtain an adequate response with the lowest effective dose.
    The usual adult dose is 15 mg to 30 mg as prescribed by the physician, at approximately 2 hours after breakfast for appetite control. Administration of one 30 mg capsule daily has been found to be adequate in depression of the appetite for 12 to 14 hours. Phentermine is not recommended for use in pediatric patient’s≤16 years of age.
    Late evening medication should be avoided because of the possibility of resulting insomnia.
    With dry hands, gently remove the Phentermine Hydrochloride Capsule from the bottle. Immediately place the Phentermine Hydrochloride Capsule on top of the tongue where it will dissolve, then swallow with or without water.



    2.2 Dosage in Patients with Renal Impairment


     The recommended maximum dosage of Phentermine Hydrochloride Capsule is 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m2). Avoid use of Phentermine Hydrochloride Capsule in patients with eGFR less than 15 mL/min/1.73m2 or end-stage renal disease requiring dialysis [see Use in Specific Populations (8.6)andClinical Pharmacology (12.3)]


  • 3 DOSAGE FORMS & STRENGTHS


    Capsules containing 15 mg or 30 mg phentermine hydrochloride (equivalent to 12 mg or 24 mg phentermine base respectively)

    15 mg Capsules: white to off-white powder filled in Size ‘3’ gray opaque/yellow opaque capsules, imprinted with “U47” on cap and body in black ink.

    30 mg Capsules: white to off-white powder filled in Size ‘3’ yellow opaque/yellow opaque capsules, imprinted with “U48” on cap and body in black ink.

  • 4 CONTRAINDICATIONS


    • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)
    • During or within 14 days following the administration of monoamine oxidase inhibitors
    • Hyperthyroidism
    • Glaucoma
    • Agitated states
    • History of drug abuse
    • Pregnancy [see Use in Specific Populations (8.1)]
    • Nursing [see Use in Specific Populations (8.3)]
    • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Coadministration with Other Drug Products for Weight Loss


    Phentermine hydrochloride Capsules are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.

    5.2 Primary Pulmonary Hypertension


    Primary Pulmonary Hypertension (PPH) - a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncopeor lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment shouldbe discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema,and patients should be evaluated for the possible presence of pulmonary hypertension.

    5.3 Valvular Heart Disease


    Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.

    5.4 Development of Tolerance, Discontinuation in Case of Tolerance


    When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.

    5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks


    Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

    5.6 Risk of Abuse and Dependence


    Phentermine is related chemically and pharmacologically to amphetamine (d- and d/l-amphetamine) and other related stimulant drugs that have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See Drug Abuse and Dependence (9)and Overdosage (10)].

     

    The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

    5.7 Usage with Alcohol


    Concomitant use of alcohol with phentermine may result in an adverse drug reaction.

    5.8 Use in Patients with Hypertension


    Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).

    5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus


    A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.

    5.10 Risk of Allergic Reactions

    This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

  • 6 ADVERSE REACTIONS

    The following adverse reactions are described, or described in greater detail, in other sections:


    The following adverse reactions to phentermine have been identified:

    Cardiovascular


    • Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.

    Central Nervous System

    •  Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.

     Gastrointestinal

    • Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

    Allergic

    • Urticaria.

    Endocrine

    • Impotence, changes in libido.
  • 7 DRUG INTERACTIONS


    Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.

    7.1 Monoamine Oxidase Inhibitors


    Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.

    7.2 Alcohol


    Concomitant use of alcohol with phentermine may result in an adverse drug reaction.

    7.3 Insulin and Oral Hypoglycemic Medications


    Requirements may be altered [see Warnings and Precautions (5.9)].

    7.4 Adrenergic Neuron Blocking Drugs


    Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy


    Pregnancy Category X

    Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and d/l-amphetamine) [see Clinical Pharmacology (12.1)]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

    8.3 Nursing Mothers


    It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    8.4 Pediatric Use


    Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.

    8.5 Geriatric Use



    In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    8.6 Renal Impairment


    Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment [seeClinical Pharmacology (12.3)].


    Use caution when administering Phentermine to patients with renal impairment. In patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m2), limit the dosage of Phentermine to 15 mg daily [see Dosage and Administration (2.2)]. Phentermine has not been studied in patients with eGFR less than 15 mL/min/1.73m2, including end-stage renal disease requiring dialysis; avoid use in these populations.



  • 9 DRUG ABUSE AND DEPENDENCE

    9.1 Controlled Substance


    Phentermine is a Schedule IV controlled substance.

    9.2 Abuse


    Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.

    9.3 Dependence


    Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

  • 10 OVERDOSAGE

    10.1 Acute Overdosage


    Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.

     

    Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard.Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine®, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.

    10.2 Chronic Intoxication


    Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See Drug Abuse and Dependence (9.3) .

  • 11 DESCRIPTION


    Phentermine hydrochloride is a sympathomimetic amine anorectic. Its chemical name is a,a,-dimethylphenethylamine hydrochloride. The structural formula is as follows:


    Structural Formula

    Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.

    Phentermine hydrochloride capsule USP is available as an oral capsule containing 15 mg or 30 mg phentermine hydrochloride (equivalent to 12 mg or 24 mg of phentermine base)

    Powder-filledcapsules containing 15 mg phentermine hydrochloride (equivalent to 12 mg phentermine) or 30 mg phentermine hydrochloride (equivalent to 24 mg phentermine) and inactive ingredients: lactose monohydrate, magnesium stearate, iron oxide black, Shellac Glaze, N-Butyl alcohol, Isopropyl alcohol, propylene Glycol and Ammonium Hydroxide.

    In addition, the 15 mg capsules contain gelatin, titanium dioxide, D&C yellow # 10, FD&C yellow # 6, FD&C red # 40, FD&C blue # 1 and FD&C yellow # 5; the 30 mg capsules contain gelatin, titanium dioxide, iron oxide yellow and iron oxide red.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action


    Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.

    12.2 Pharmacodynamics


    Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

    12.3 Pharmacokinetics

    Following the administration of phentermine, phentermine reaches peak concentrations (Cmax) after 3 to 4.4 hours. 

    Drug Interactions

    In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine Cmax and AUC increase 13% and 42%, respectively.

    Specific Populations

    Renal Impairment

    Cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions was 62% to 85%.

    Systemic exposure of phentermine may increase up to 91%, 45%, and 22% in patients with severe, moderate, and mild renal impairment, respectively [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].



  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility


    Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.

  • 14 CLINICAL STUDIES


    In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with “anorectic” drugs lost more weight on the average than those treated with placebo and diet.

    The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an “anorectic” drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

    The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks’ duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Phentermine Hydrochloride Capsules USP, 15 mg are white to off-white powder filled in Size ‘3’ gray opaque/yellow opaque capsules, imprinted with “U47” on cap and body in black ink.

    Bottles of 30               NDC: 13107-105-30

    Bottles of 100             NDC: 13107-105-01

    Phentermine Hydrochloride Capsules USP, 30 mg are white to off-white powder filled in Size ‘3’ yellow opaque/yellow opaque capsules, imprinted with “U48” on cap and body in black ink.

    Bottles of 30               NDC: 13107-106-30

    Bottles of 100             NDC: 13107-106-01




    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.

    Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

    Keep out of the reach of children.

  • 17 PATIENT COUNSELING INFORMATION

    Patients must be informed that phentermine hydrochloride is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [seeIndications and Usage (1)and Warnings and Precautions (5)].

    Patients must be instructed on how much phentermine to take, and when and how to take it [see Dosage and Administration (2)].

    Advise pregnant women and nursing mothers not to use phentermine [see Use in Specific Populations (8.1, 8.3)].

    Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:

    See also, for example, Adverse Reactions (6)and Use in Specific Populations (8) .

    The patients must also be informed about

    Tell patients to keep phentermine in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.

    Revised:03/2017

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL –Phentermine Hydrochloride Capsules, USP 15 mg - 100 Capsules Label Text


    NDC: 13107-105-30
    Phentermine Hydrochloride Capsules, USP CIV
    15 mg 

    Rx only         30 Capsules



    phentermine3-fig1
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL – Phentermine Hydrochloride Capsules, USP 30 mg - 100 Capsules Label Text

    NDC: 13107-106-30
    Phentermine Hydrochloride Capsules, USP CIV
    30 mg

     Rx only          30 Capsules



    phentermine3-fig2





     


  • INGREDIENTS AND APPEARANCE
    PHENTERMINE 
    phentermine hydrochloride capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-105
    Route of AdministrationORALDEA ScheduleCIV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHENTERMINE HYDROCHLORIDE (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP) PHENTERMINE HYDROCHLORIDE15 mg
    Inactive Ingredients
    Ingredient NameStrength
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    GELATIN (UNII: 2G86QN327L)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C YELLOW NO. 5 (UNII: I753WB2F1M)  
    SHELLAC (UNII: 46N107B71O)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    BUTYL ALCOHOL (UNII: 8PJ61P6TS3)  
    ISOPROPYL ALCOHOL (UNII: ND2M416302)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    AMMONIA (UNII: 5138Q19F1X)  
    Product Characteristics
    ColorGRAY (Gray Opaque) , YELLOW (Yellow Opaque) Scoreno score
    ShapeCAPSULESize16mm
    FlavorImprint Code U;47
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-105-3030 in 1 BOTTLE; Type 0: Not a Combination Product03/20/2017
    2NDC: 13107-105-01100 in 1 BOTTLE; Type 0: Not a Combination Product03/20/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20431803/20/2017
    PHENTERMINE 
    phentermine hydrochloride capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-106
    Route of AdministrationORALDEA ScheduleCIV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHENTERMINE HYDROCHLORIDE (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP) PHENTERMINE HYDROCHLORIDE30 mg
    Inactive Ingredients
    Ingredient NameStrength
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    GELATIN (UNII: 2G86QN327L)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    SHELLAC (UNII: 46N107B71O)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    BUTYL ALCOHOL (UNII: 8PJ61P6TS3)  
    ISOPROPYL ALCOHOL (UNII: ND2M416302)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    AMMONIA (UNII: 5138Q19F1X)  
    Product Characteristics
    ColorYELLOW (Yellow Opaque) Scoreno score
    ShapeCAPSULESize16mm
    FlavorImprint Code U;48
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-106-3030 in 1 BOTTLE; Type 0: Not a Combination Product03/20/2017
    2NDC: 13107-106-01100 in 1 BOTTLE; Type 0: Not a Combination Product03/20/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20431803/20/2017
    Labeler - Aurolife Pharma, LLC (829084461)
    Establishment
    NameAddressID/FEIBusiness Operations
    Aurolife Pharma, LLC829084461MANUFACTURE(13107-105, 13107-106)
    Establishment
    NameAddressID/FEIBusiness Operations
    Aurolife Pharma LLC078296263RELABEL(13107-105, 13107-106) , REPACK(13107-105, 13107-106) , LABEL(13107-105, 13107-106) , PACK(13107-105, 13107-106)

    • Trademark Results [Phentermine]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    PHENTERMINE
    PHENTERMINE
    85205660 not registered Dead/Abandoned
    Folkins, Lee
    2010-12-26
    PHENTERMINE
    PHENTERMINE
    78518794 not registered Dead/Abandoned
    erin riggins
    2004-11-17
    PHENTERMINE
    PHENTERMINE
    77444554 not registered Indifferent
    Merritt Ambrose
    0000-00-00
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.